United Kingdom Archives

News and Trends 8 Feb 2018

GSK’s Company Starts Phase III Trials with Two-Drug HIV Treatment

ViiV Healthcare has just started a clinical trial to test if its two-drug regimen for HIV can work as well as current three-drug HIV treatment. Most antiretroviral treatments used to keep HIV at bay employ a combination of three different drugs, exposing patients to the long-term toxicity of three different compounds at once. London-based ViiV […]

February 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Feb 2018

Scottish CAR-T Biotech Adds Another Stellar Partner to Its Roster

TC Biopharm has signed a new pharma partner, the Japan-based NIPRO Corporation, who will give the biotech a leg up in the CAR-T game. Hot on the heels of the two huge CAR-T acquisitions of Juno and Kite, Japanese pharma NIPRO Corporation is planting a foot in the game by partnering with Scotland-based TC Biopharm […]

February 7, 2018 - 1 minutemin - By Evelyn Warner

News and Trends 6 Feb 2018

Spring Cleaning: AstraZeneca Ditches Underperforming Asthma and Cancer Candidates

AstraZeneca has given up on the development of its PD-1 checkpoint inhibitor drug, which was the headline act when its subsidiary MedImmune acquired Amplimmune in 2013. There was no sentiment as pharma giant AstraZeneca cut a number of drugs from its pipeline after they did not perform as expected during clinical trials. The biggest name to get […]

February 6, 2018 - 3 minutesmins - By Alex Dale

News and Trends 5 Feb 2018

New Antiviral for RSV Lung Infections Shows Promise in Phase IIa

ReViral’s candidate RV521 showed its potential for the treatment of respiratory syncytial virus (RSV) infections by reducing viral load and mucus levels. London-based biotech ReViral discovers and develops antiviral drugs, focusing particularly on the treatment of diseases caused by the respiratory syncytial virus (RSV). The biotech’s candidate, RV521, has undergone a Phase IIa clinical trial during […]

February 5, 2018 - 3 minutesmins - By Alex Dale

lig biowise diagnostics antimicrobial resistance

More News! 5 Feb 2018

A DNA-Based Diagnostic Company Rakes in £1.8M to Combat Antimicrobial Resistance

A new molecular diagnostics company, LIG Biowise, has just closed a £1.8M Series A fundraising round in its effort to combat antimicrobial resistance. Based in Manchester, LIG Biowise, is working on a DNA-based diagnostic to catch antibiotic resistant infections early. The company has now closed a Series A of £1.8M (€2.0M), led by Hong Kong-based Phoenix Bridge, to fund […]

February 5, 2018 - 1 minutemin - By Evelyn Warner

News and Trends 31 Jan 2018

Your Pee Could Be Used to Build an Artificial Adrenal Gland

Scientists have started generating artificial glands using cells derived from urine, which will allow the study of adrenal disorders that affect growth, development, and metabolism. Researchers at Queen Mary University of London have used cells in urine to begin generating an artificial adrenal gland that could be used to treat adrenal gland disorders. The study, published in Cell Reports, […]

January 31, 2018 - 3 minutesmins - By Alex Dale

News and Trends 31 Jan 2018

Gene Synthesizing Biotech Gets $12M to Boost the Synbio Field

Evonetix has closed a Series A fundraising round to support the development of its gene synthesis platform, an important tool in the emerging synbio field. Evonetix, based in Cambridge, UK, is developing a scalable, high fidelity gene synthesis approach that could be a key tool in the growing synbio field. The biotech has closed a […]

January 31, 2018 - 3 minutesmins - By Alex Dale

News and Trends 30 Jan 2018

Update: Pocket Device makes its Debut in Whole Human Genome Sequencing

Update (30/01/2018): Oxford Nanopore has published a study in Nature Biotechnology outlining the first use of its pocket MinION device to sequence a human genome. The device was able to read sequences of DNA that are “hundreds of times larger than usual,” helping scientists better reconstruct the whole genome sequence. MinION costs less than $1,000 and […]

January 30, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Jan 2018

London Tops Europe for Life Sciences Investment in 2017

Investment in London’s life sciences companies reached almost £1B in 2017, beating the likes of Berlin and Paris to top spot. A new study has found that London’s life sciences industry received the most investment out of any city in Europe in 2017. Over the last 5 years, companies in the capital have raised £2.8Bn (€3.2Bn), with £909M […]

January 29, 2018 - 3 minutesmins - By Alex Dale

News and Trends 26 Jan 2018

New British Spinout May Get Snapped Up by Allergan for $400M

KaNDy Therapeutics, a women’s health spinout helmed by Mary Kerr, is rumored to be in acquisition talks that value the company at $400M (€322M). Details are sparse, but according to a report from Bloomberg, Stevenage-based KaNDy Therapeutics is supposedly in the late stages of a discussion with Allergan about a possible buyout. KaNDy, a recent spinout […]

January 26, 2018 - 1 minutemin - By Evelyn Warner

News and Trends 25 Jan 2018

Yet More Good News for GW Pharma’s Cannabinoid Drug Against Epilepsy

New data in The Lancet provides further support for GW Pharma’s drug, Epidiolex, for the treatment of a rare form of epilepsy. GW Pharmaceuticals has achieved encouraging Phase III results for Epidiolex, which have been published in leading scientific journal, The Lancet. The company’s lead candidate is being developed for the treatment of epilepsy – a […]

January 25, 2018 - 3 minutesmins - By Alex Dale

News and Trends 25 Jan 2018

British Biotech Treats First Phase III Patient in its Critical Limb Ischemia Trial

Rexgenero has treated the first patient in a Phase III trial investigating REX-001, the biotech’s cell therapy for critical limb ischemia. Rexgenero is a biotech working on regenerative medicine techniques to treat critical limb ischemia (CLI). The condition is characterized by blocked arteries in the lower limbs that can force doctors to amputate. The company has […]

January 25, 2018 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

GSK’s Company Starts Phase III Trials with Two-Drug HIV Treatment

Scottish CAR-T Biotech Adds Another Stellar Partner to Its Roster

Spring Cleaning: AstraZeneca Ditches Underperforming Asthma and Cancer Candidates

New Antiviral for RSV Lung Infections Shows Promise in Phase IIa

A DNA-Based Diagnostic Company Rakes in £1.8M to Combat Antimicrobial Resistance

Your Pee Could Be Used to Build an Artificial Adrenal Gland

Gene Synthesizing Biotech Gets $12M to Boost the Synbio Field

Update: Pocket Device makes its Debut in Whole Human Genome Sequencing

London Tops Europe for Life Sciences Investment in 2017

New British Spinout May Get Snapped Up by Allergan for $400M

Yet More Good News for GW Pharma’s Cannabinoid Drug Against Epilepsy

British Biotech Treats First Phase III Patient in its Critical Limb Ischemia Trial

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!